Age-related immune dysregulation and late loss of tolerance could be particularly relevant for the nonsevere hemophilia cohort, as exposure to therapeutic FVIII concentrates is distributed throughout a lifetime and often skewed toward later decades for elective operative interventions. The gene discussed is F8; the disease is hemophilia.